Sino Biological Unveils Innovative Protein Collections for AI-Driven Research
Sino Biological, Inc., a global leader in the biotechnology sector, recently announced the launch of two innovative collections of target proteins specifically tailored for AI-driven research. With the rapid advancements in artificial intelligence (AI), the need for well-characterized recombinant proteins and antibodies has never been greater. These proteins will play a crucial role in assessing molecules designed through AI techniques, facilitating therapeutic and diagnostic advancements.
The first collection, known as AI-validated proteins, comprises more than 600 targets and over 960 individual proteins. These have been rigorously tested in various validation projects, evidencing their usefulness in AI-focused research. Comprehensive characterization data is available for each protein, which could include analyses via Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (BLI), Enzyme-Linked Immunosorbent Assay (ELISA), cell-based activity assays, Size Exclusion High-Performance Liquid Chromatography (SEC-HPLC), and Multi-Angle Light Scattering (SEC-MALS).
The second collection, labeled as AI-ready proteins, features experimentally characterized target-binding activity, complete with validation data through SPR and BLI. This collection encompasses over 680 targets and more than 1,700 individual proteins. It provides researchers with a substantial choice of well-characterized target proteins aimed at evaluating AI-designed molecules effectively.
Central to these offerings is Sino Biological's 4S system, which emphasizes Scale, Scope, Speed, and Supply. This dynamic framework supports over 11,000 recombinant target proteins, ensuring vast target coverage, diverse protein formats, and a reliable long-term supply for AI-driven research programs. Additionally, Sino Biological has curated a catalog of therapeutic targets spanning 12 therapeutic areas and more than 100 diseases, allowing researchers to explore pertinent targets according to therapeutic domains or specific diseases.
Sino Biological's commitment to facilitating AI-validated research is further exemplified by their 4RISE™ solution. This initiative aims to seamlessly connect resources and AI validation from beginning to end, integrating lab-based AI validation with large-scale protein expression, binding characterization, development viability assessment, and functional validation.
4RISE™ is built upon four core pillars: speed, depth, fluidity, and empiricism, offering comprehensive experimental lab support aimed at guiding researchers as they transition AI-designed molecules from computational predictions to experimental evidence.
Dr. Rob Burgess, commercial director of Sino Biological US, stated, "AI-driven discovery relies heavily on reliable experimental resources to evaluate designed molecules and guide subsequent research decisions. By combining AI-validated and AI-ready target proteins with our 4S system, we aim to provide researchers with well-characterized target resources, extensive coverage, and constant supply to support AI-driven protein and antibody discovery."
With these pioneering collections, Sino Biological clearly positions itself as a frontrunner in the rapidly evolving realm of biotechnology, driving forward significant advancements in therapeutic and diagnostic research powered by artificial intelligence.